People can now monitor and trend immune system response to their gluten-free diet from the comfort of home
HOUSTON (PRWEB) JANUARY 21, 2019
imaware™, an at-home testing platform for chronic illness and diseases designed by healthcare company Microdrop, today announced it has expanded its line of tests for people with Celiac Disease. The platform now includes an easy-to-use monitoring test for those who have been diagnosed and want to track the progress of their diet and lifestyle changes. The new monitoring test follows the company’s recent launch of its Celiac Disease screening test to provide people with comprehensive end-to-end testing and disease management tools for the autoimmune disease.
“Celiac disease remains a highly underdiagnosed autoimmune disease affecting millions, with an estimated 60 percent who are not yet diagnosed,” said Jani Tuomi, co-founder. “For those that are diagnosed, more than 70 percent of people do not conduct follow-up testing to validate healing. Our goal is to eliminate the economical and accessibility issues associated with proper medical testing, by empowering people to perform tests in their home and manage the ongoing progress of their disease.”
The imaware™ Celiac Disease screening and monitoring kits make it easy for people to obtain the information they need from the comfort of their own home. Using just a few drops of blood, the test measures the same antibodies to gluten that are provided in traditional medical lab testing. The results are reviewed by a team of health professionals, and provided to the patient through the online imaware portal.
Designed alongside world-renowned doctors, “imaware™ is a simple and precise at-home screening test for celiac disease that should significantly reduce the number of undiagnosed patients over time,” said Dr. Guandalini, Medical Director of the University of Chicago Celiac Disease Center and advisor to imaware. “Additionally, imaware supports monitoring using the same type of tests that are currently requested by healthcare professionals for their patients. Such monitoring is considered important in checking the post-diagnosis adherence to the diet as well as its effectiveness.”
imaware™ has also partnered with Beyond Celiac, the nation’s leading patient advocacy organization, to expand celiac disease education and access to at-home testing in order to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure.
How imaware™ for Celiac Disease works:
The imaware tests measure the same antibodies related to celiac disease as the tests that doctors use, measuring the “gold standard” anti-tissue Transglutaminase (tTG) biomarkers, as well as Deamidated Gliadin Peptide (DGP) biomarkers to provide a more comprehensive result. Available online at imaware.health, the imaware test uses a small amount of blood obtained by a finger prick and collected in a vial. People then mail the sample back in and within 5 days will receive their confidential test results via a secure portal. The imaware™ at-home test for celiac disease screening and monitoring are both available at imaware.health for $99 USD each. The test is currently available in the United States.
The imaware mission is to provide patients with the tools to drive awareness to chronic illness and empower patients to live a better and healthier life – sooner. Each imaware test is designed and validated alongside world-renowned doctors from the most prestigious medical research facilities including Dr. Eleftherios Diamandis of Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Dr. Stefano Guandalini University of Chicago Celiac Disease Center, and Dr. Melissa Bondy and Dr. Margaret Spitz Of Baylor College of Medicine.
For more information, visit us online at imaware.health